Chemo showdown: short High-Dose vs long Low-Dose for childhood muscle cancer
NCT ID NCT07466316
First seen Mar 20, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study compares two chemotherapy approaches for people up to age 50 with newly diagnosed intermediate-risk rhabdomyosarcoma, a type of muscle cancer. One group gets a higher dose of chemo over a shorter time, while the other gets a lower dose over a longer time plus extra maintenance drugs. The goal is to see which plan works better at controlling the cancer and improving survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.